Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Samarium-153 in High Risk Osteogenic Sarcoma
NCT00245011Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2004
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of samarium-153 lexidronam in osteosarcoma (OS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Tumor Response and Correlative Dose of Radiation by Low Dose and High Dose Samarium-153. Started Oct 2004; status: completed.
02
Drugs
samarium-153 lexidronam
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00245011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245011.